Oral manifestations produced by the consumption of drugs administered within the palliative treatment of Covid-19: bibliographic review.
DOI:
https://doi.org/10.26871/killcanasalud.v6i3.622Keywords:
Covid-19, Manifestaciones orales, Hidroxicloroquina, Cloroquina, Enfermedades sistémicas.Abstract
Introduction: Coronavirus (Covid-19) is a microscopic acellular infectious agent; considered as a respiratory virus that begins its infection from the throat when it enters our body; by means of the eyes, mouth or nose it is possible to hold the mucosa cells particularly from the nose and throat; This virus has the ability to replicate, because once the copies are made they leave the cell where they originated, destroy it and begin to infect other cells. Objective: To identify the oral manifestations produced by the consumption of drugs administered within the palliative treatment of COVID-19. Materials and Methods: This study is descriptive, cross-sectional, retrospective. Conclusion: The research carried out determines that the consumption of drugs implemented for the palliative treatment of COVID-19, such as Hydroxychloroquine, Chloroquine and Remdesivir, produce manifestations in the oral cavity such as dental abrasion, pigmentation, xerostomia and lichen planus.Downloads
Download data is not yet available.
References
1. Awadhesh Kumar, et al. Cloroquina e hidroxicloroquina en el tratamiento de COVID-19 con o sin diabetes: una búsqueda sistemática y una revisión narrativa con una referencia especial a la India y otros países en desarrollo. Rev. El Seiver [Internet] (14) 3, 241-246. https://doi.org/10.1016/j.dsx.2020.03.011
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. J Am Med Assoc 2020 Feb 24. https://doi.org/10.1001/jama.2020.2648.
3. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic. carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect 2020 Mar 4;(20). https://doi.org/10.1016/j.jmii.2020.02.012.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15;395. https://doi.org/10.1016/S0140-6736(20)30183-5
5. Alejandro Carlos de la Parte-Serna 1 ; Gonzalo Oliván-Gonzalvo. (2020). La atención bucodental en atención primaria del sistema aragonés de salud durante el brote de covid-19. Rev. Europea De Odontoestomatologia, REDOE, 17/04/2020. Disponible en: http://www.redoe.com/ver.php?id=312
6. Milagros de la Caridad C, Dr. Jorge Laurencio R, Dra. Maritza Peña S. Enfermedades causadas por fármacos en la cavidad bucal. [Internet]. 2015 [citado 2020 Mayo 09]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S102930192015001100013
7. Yuan A, Woo SB. Adverse drug events in the oral cavity. [Internet]. 2015[citado 2020 Mayo 09]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25442252
8. Géssica Vasconcelos G, Ana Luiza Lima Medeiros P. Extensive hard palate hyperpigmentation associated with chloroquine use. [Internet]. 2020[citado 2020 Mayo 09]. Disponible en: https://bpspubs.nlinelibrary.wiley.com/doi/full/10.1111/bcp.14313
9. Sedigheh B, Marziye S. Orofacial manifestations of adverse drug reactions: a review study. [Internet]. 2018[citado 2020 Mayo 09]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808263/
10. James M. Sanders. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)A Review. [Internet]. 2020[citado 2020 Mayo 09]. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2764727
11. Siccandar J. Corticosteroids in Oral and Maxillofacial Lesions – A Review. [Internet]. 2019[citado 2020 Mayo 09]. Disponible en: https://lupinepublishers.com/anesthesia-pain-medicine journal/fulltext/corticosteroids-in-oral-and-maxillofacial-lesions-a- review.ID.000112.php
12. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020 Mar 4:105932. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105932
13. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (CoV) in vitro. Cell Res 2020. Disponible en: https://doi.org/10.1038/s41422e020e0282e0.
14. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus. Int J Antimicrob Agents 2020 Feb 17. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105923.
15. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a les toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16. Disponible en: https://doi.org/10.1038/s41421-020-0156-0.
16. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2). ClinInfect Dis 2020 Mar 9. Disponible en: https://doi.org/10.1093/cid/ciaa237.
17. Gautret P, Lagiera JC, Parolaa P, Hoanga VT, Meddeba L, Mailhea M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Int J Antimicrob Agents17 March 2020. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949.
18. Rimesh Pal Sanjay K. Bhadada. (2020). COVID-19 y diabetes mellitus: una interacción impía de dos pandemias. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Rev. ElSeiver, Volume 14, Issue 4, July– August 2020, 513-517. Disponible en: https://doi.org/10.1016/j.dsx.2020.04.049
19. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes, Metab Syndrome Clin Res Rev 2020 Mar 10;14(3):211 Disponible en: https://pubmed.ncbi.nlm.nih.gov/32172175/
20. Qianwen Zhao Yang et al. La linfopenia se asocia con infecciones graves por enfermedad por coronavirus 2019 (COVID-19): una revisión sistémica. y un metaanálisis. Rev. ElSeiver 4 de mayo de 2020. (20) 30-31. Disponible en: https://doi.org/10.1016/j.ando.2020.04.005
21. Sameep S., Shetty Vishal Ra, Akshay Kudpaje, Surya Mithra, Yash Merchant, Nikita Shabadi. Una perspectiva oncóloga sobre COVID 19: un misterioso virus críptico. Oncología oral. Disponible en: https://doi.org/10.1016/j.oraloncology.2020.104694
22. Maryam Baghizadeh Fini. (2020) Lo que los dentistas necesitan saber sobre COVID-19. Oncología oral, Rev. ElSeiver, Volumen 105 , junio de 2020 , 104741. Disponible en: https://doi.org/10.1016/j.oraloncology.2020.104741
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. J Am Med Assoc 2020 Feb 24. https://doi.org/10.1001/jama.2020.2648.
3. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic. carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect 2020 Mar 4;(20). https://doi.org/10.1016/j.jmii.2020.02.012.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15;395. https://doi.org/10.1016/S0140-6736(20)30183-5
5. Alejandro Carlos de la Parte-Serna 1 ; Gonzalo Oliván-Gonzalvo. (2020). La atención bucodental en atención primaria del sistema aragonés de salud durante el brote de covid-19. Rev. Europea De Odontoestomatologia, REDOE, 17/04/2020. Disponible en: http://www.redoe.com/ver.php?id=312
6. Milagros de la Caridad C, Dr. Jorge Laurencio R, Dra. Maritza Peña S. Enfermedades causadas por fármacos en la cavidad bucal. [Internet]. 2015 [citado 2020 Mayo 09]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S102930192015001100013
7. Yuan A, Woo SB. Adverse drug events in the oral cavity. [Internet]. 2015[citado 2020 Mayo 09]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25442252
8. Géssica Vasconcelos G, Ana Luiza Lima Medeiros P. Extensive hard palate hyperpigmentation associated with chloroquine use. [Internet]. 2020[citado 2020 Mayo 09]. Disponible en: https://bpspubs.nlinelibrary.wiley.com/doi/full/10.1111/bcp.14313
9. Sedigheh B, Marziye S. Orofacial manifestations of adverse drug reactions: a review study. [Internet]. 2018[citado 2020 Mayo 09]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808263/
10. James M. Sanders. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)A Review. [Internet]. 2020[citado 2020 Mayo 09]. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2764727
11. Siccandar J. Corticosteroids in Oral and Maxillofacial Lesions – A Review. [Internet]. 2019[citado 2020 Mayo 09]. Disponible en: https://lupinepublishers.com/anesthesia-pain-medicine journal/fulltext/corticosteroids-in-oral-and-maxillofacial-lesions-a- review.ID.000112.php
12. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020 Mar 4:105932. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105932
13. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (CoV) in vitro. Cell Res 2020. Disponible en: https://doi.org/10.1038/s41422e020e0282e0.
14. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus. Int J Antimicrob Agents 2020 Feb 17. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105923.
15. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a les toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16. Disponible en: https://doi.org/10.1038/s41421-020-0156-0.
16. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2). ClinInfect Dis 2020 Mar 9. Disponible en: https://doi.org/10.1093/cid/ciaa237.
17. Gautret P, Lagiera JC, Parolaa P, Hoanga VT, Meddeba L, Mailhea M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Int J Antimicrob Agents17 March 2020. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949.
18. Rimesh Pal Sanjay K. Bhadada. (2020). COVID-19 y diabetes mellitus: una interacción impía de dos pandemias. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Rev. ElSeiver, Volume 14, Issue 4, July– August 2020, 513-517. Disponible en: https://doi.org/10.1016/j.dsx.2020.04.049
19. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes, Metab Syndrome Clin Res Rev 2020 Mar 10;14(3):211 Disponible en: https://pubmed.ncbi.nlm.nih.gov/32172175/
20. Qianwen Zhao Yang et al. La linfopenia se asocia con infecciones graves por enfermedad por coronavirus 2019 (COVID-19): una revisión sistémica. y un metaanálisis. Rev. ElSeiver 4 de mayo de 2020. (20) 30-31. Disponible en: https://doi.org/10.1016/j.ando.2020.04.005
21. Sameep S., Shetty Vishal Ra, Akshay Kudpaje, Surya Mithra, Yash Merchant, Nikita Shabadi. Una perspectiva oncóloga sobre COVID 19: un misterioso virus críptico. Oncología oral. Disponible en: https://doi.org/10.1016/j.oraloncology.2020.104694
22. Maryam Baghizadeh Fini. (2020) Lo que los dentistas necesitan saber sobre COVID-19. Oncología oral, Rev. ElSeiver, Volumen 105 , junio de 2020 , 104741. Disponible en: https://doi.org/10.1016/j.oraloncology.2020.104741
Downloads
Published
2022-09-01
ESTADISTICAS
- Abstract 65
- DESCARGAR PDF (Español (España)) 60
How to Cite
Játiva Bravo, O. E., Carrión Arias, R. A., Castro Vásquez, J. A., & Sánchez Zamora, V. R. (2022). Oral manifestations produced by the consumption of drugs administered within the palliative treatment of Covid-19: bibliographic review. Killkana Salud Y Bienestar, 6(3), 129–140. https://doi.org/10.26871/killcanasalud.v6i3.622
Issue
Section
Artículos de revisión bibliográfica
